Article Text

PDF
FRI0502 Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab
  1. B. Toz1,
  2. M. İnanç1,
  3. N. Senturk2,
  4. B. Erer1,
  5. B. Artım Esen1,
  6. S. Kamali1,
  7. L. Ocal1,
  8. A. Gül1
  1. 1Division of Rheumatology Istanbul School of Medicine, Istanbul University
  2. 2Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey

Abstract

Background There is no randomized controlled trial data to guide us for the management of Adult Still's Disease (AOSD) patients refractory to conventional treatments.

Objectives We herein aimed to analyze retrospectively the treatment results of a series of refractory AOSD patients, who received different biologics.

Methods We screened our database for patients diagnosed with AOSD between 1987–2015, and reviewed charts of those patients refractory to corticosteroid and DMARD combination and received biologics including TNF, IL-1 and IL-6 inhibitors. Patients were grouped according to their first biologics as TNF-inhibitors (TNF-i) or others [anakinra (ANK) or tocilizumab (TCZ)]. We also analyzed the patient responses according to their disease course characteristics as polycyclic or chronic patients. Time to remission were analysed by Kaplan-Meier method, and the association of response with first biological treatment was analysed by regression analysis

Results Twenty-four patients with refractory AOSD (chronic=9 and polycyclic=15),who received biologic treatments with a mean duration of 41±27 months. The first biological treatment was TNF-i in 14 and other agents in 10 (ANK in 7 and TCZ in 3).Of the patients,50% were switched from TNF-i to ANK or TCZ. Comparison of the patients according to their first biologic therapy is given in Table 1. The patients who received other biologics were associated with a better response as the first treatment and tended to achieve remission earlier compared with those who received TNF-i as their first biological treatment (median time to remission 4 vs, 8 months, log-rank p=0.44). Joint involvement was more common and skin involvement tended to be more common in the chronic course group (100% vs 50%,78% vs 36%, respectively). While the duration of biologic treatment tended to be longer in the chronic course group (51 mo vs 28 mo,p=0.04), duration of remission was similar between the groups (26 mo vs 20 mo, p=0.4). The remission rate tended to be higher in the polycyclic group, whereas CRP and ESH tended to be lower in the chronic group. Complete remission rates under biologics course were as follows: 63% with TCZ 8mg/kg (7/11), 61% with ANK 100–200mg (11/18), 27% with etanercept (3/11), and 9% with infliximab (1/11) treatments. Regression analysis showed that selection of TCZ or ANK biologics as the first biologic was associated with a better response independent of the disease course type (estimate 2.5, 95% CI 0.3–4.7, p=0.026).No serious infection was observed in patients treated with biologics. In two patients severe skin reactions occurred with ANK and infliximab and, in one patient an immune thrombocytopenia developed under TCZ treatment.

Conclusions This case series of AOSD patients suggest that ANK and TCZ seem to be better treatment choices in terms of remission rate and time to remission in patients refractory to conventional treatments

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.